BVNRY
Price
$12.31
Change
+$0.07 (+0.57%)
Updated
Sep 5 closing price
Capitalization
2.88B
IPHA
Price
$2.05
Change
-$0.05 (-2.38%)
Updated
Sep 5, 04:50 PM (EDT)
Capitalization
197.73M
12 days until earnings call
Interact to see
Advertisement

BVNRY vs IPHA

Header iconBVNRY vs IPHA Comparison
Open Charts BVNRY vs IPHABanner chart's image
Bavarian Nordic A/S
Price$12.31
Change+$0.07 (+0.57%)
Volume$4.87K
Capitalization2.88B
Innate Pharma SA
Price$2.05
Change-$0.05 (-2.38%)
Volume$1.5K
Capitalization197.73M
BVNRY vs IPHA Comparison Chart in %
Loading...
BVNRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BVNRY vs. IPHA commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BVNRY is a Hold and IPHA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (BVNRY: $12.24 vs. IPHA: $2.10)
Brand notoriety: BVNRY and IPHA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BVNRY: 49% vs. IPHA: 119%
Market capitalization -- BVNRY: $2.88B vs. IPHA: $197.73M
BVNRY [@Biotechnology] is valued at $2.88B. IPHA’s [@Biotechnology] market capitalization is $197.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BVNRY’s FA Score shows that 0 FA rating(s) are green whileIPHA’s FA Score has 1 green FA rating(s).

  • BVNRY’s FA Score: 0 green, 5 red.
  • IPHA’s FA Score: 1 green, 4 red.
According to our system of comparison, BVNRY is a better buy in the long-term than IPHA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BVNRY’s TA Score shows that 4 TA indicator(s) are bullish while IPHA’s TA Score has 2 bullish TA indicator(s).

  • BVNRY’s TA Score: 4 bullish, 4 bearish.
  • IPHA’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, BVNRY is a better buy in the short-term than IPHA.

Price Growth

BVNRY (@Biotechnology) experienced а -0.69% price change this week, while IPHA (@Biotechnology) price change was +0.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.44%. For the same industry, the average monthly price growth was +9.90%, and the average quarterly price growth was +31.78%.

Reported Earning Dates

IPHA is expected to report earnings on Sep 17, 2025.

Industries' Descriptions

@Biotechnology (+2.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BVNRY($2.88B) has a higher market cap than IPHA($198M). BVNRY YTD gains are higher at: 41.391 vs. IPHA (13.913).
BVNRYIPHABVNRY / IPHA
Capitalization2.88B198M1,456%
EBITDA2.01BN/A-
Gain YTD41.39113.913297%
P/E Ratio13.13N/A-
Revenue6.23BN/A-
Total Cash1.24BN/A-
Total Debt117MN/A-
FUNDAMENTALS RATINGS
BVNRY vs IPHA: Fundamental Ratings
BVNRY
IPHA
OUTLOOK RATING
1..100
7780
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
6298
PRICE GROWTH RATING
1..100
4377
P/E GROWTH RATING
1..100
9433
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BVNRY's Valuation (45) in the null industry is in the same range as IPHA (75). This means that BVNRY’s stock grew similarly to IPHA’s over the last 12 months.

BVNRY's Profit vs Risk Rating (83) in the null industry is in the same range as IPHA (100). This means that BVNRY’s stock grew similarly to IPHA’s over the last 12 months.

BVNRY's SMR Rating (62) in the null industry is somewhat better than the same rating for IPHA (98). This means that BVNRY’s stock grew somewhat faster than IPHA’s over the last 12 months.

BVNRY's Price Growth Rating (43) in the null industry is somewhat better than the same rating for IPHA (77). This means that BVNRY’s stock grew somewhat faster than IPHA’s over the last 12 months.

IPHA's P/E Growth Rating (33) in the null industry is somewhat better than the same rating for BVNRY (94). This means that IPHA’s stock grew somewhat faster than BVNRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BVNRYIPHA
RSI
ODDS (%)
Bearish Trend 1 day ago
61%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
59%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 18 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
69%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BVNRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIVMX13.23N/A
N/A
Fidelity Advisor International Value A
TWCUX100.13N/A
N/A
American Century Ultra® Inv
MARFX24.11N/A
N/A
BlackRock Mid-Cap Value Institutional
ALSRX16.83N/A
N/A
Alger Small Cap Growth Institutional I
NOLCX32.32N/A
N/A
Northern Large Cap Core

BVNRY and

Correlation & Price change

A.I.dvisor tells us that BVNRY and GOVX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BVNRY and GOVX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BVNRY
1D Price
Change %
BVNRY100%
+0.57%
GOVX - BVNRY
28%
Poorly correlated
-5.52%
CRMD - BVNRY
24%
Poorly correlated
-3.13%
VRAX - BVNRY
23%
Poorly correlated
-6.87%
DMAC - BVNRY
22%
Poorly correlated
+14.34%
IPHA - BVNRY
21%
Poorly correlated
-2.20%
More